Literature DB >> 35346312

Molecular brain (micro report) oxytocin ameliorates impaired social behavior in a mouse model of 3q29 deletion syndrome.

Tomoya Takemoto1, Masayuki Baba1, Kazumasa Yokoyama2, Kohei Kitagawa1, Kazuki Nagayasu1,3, Yukio Ago4, Kaoru Seiriki1,5, Atsuko Hayata-Takano1,6, Atsushi Kasai1, Daisuke Mori7,8, Norio Ozaki7, Kazuhiro Takuma6,9, Ryota Hashimoto10, Hitoshi Hashimoto11,12,13,14,15,16, Takanobu Nakazawa17,18,19.   

Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by specific social symptoms, restricted interests, stereotyped repetitive behaviors, and delayed language development. The 3q29 microdeletion (3q29del), a recurrent copy number variant, confers a high risk for ASD and schizophrenia, and serves as an important pathological model for investigating the molecular pathogenesis of a large number of neurodevelopmental and psychiatric conditions. Recently, mouse models carrying a deletion of the chromosomal region corresponding to the human 3q29 region (Df/+ mice) were generated and demonstrated neurodevelopmental and psychiatric conditions associated behavioral abnormalities, pointing to the relevance of Df/+ mice as a model for these conditions with high construct and face validity. Currently, the molecular pathogenesis of these behavioral phenotypes in Df/+ mice remains unclear. The oxytocin (OXT) system plays a central role in social behavior across species and has a potential role in ASD. In this study, to elucidate the molecular mechanisms behind impaired social behavior in Df/+ mice, we investigated the possible involvement of OXT signaling in impaired social behavior in Df/+ mice. We demonstrated that OXT administration restored the impaired social behavior in Df/+ mice. We also demonstrated that the number of OXT-positive cells in the paraventricular nucleus (PVN) was significantly lower in Df/+ mice than in wild-type (WT) littermates. Consistent with this, the level of OXT peptide in the cerebral cortex of Df/+ mice was lower than in WT littermates. Our study may provide important insights into the molecular pathophysiological basis of neurodevelopmental and psychiatric conditions, including ASD.
© 2022. The Author(s).

Entities:  

Keywords:  3q29 microdeletion; Autism spectrum disorder; Oxytocin; Paraventricular nucleus; Social behavior

Mesh:

Substances:

Year:  2022        PMID: 35346312      PMCID: PMC8962454          DOI: 10.1186/s13041-022-00915-w

Source DB:  PubMed          Journal:  Mol Brain        ISSN: 1756-6606            Impact factor:   4.399


Introduction

Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by specific social symptoms, restricted interests, stereotyped repetitive behaviors, and delayed language development [1]; its incidence is increasing worldwide [2]. Although recent genetic studies have identified high-confidence ASD-associated genetic variants [3], the molecular pathogenesis of ASD remains unclear [1]. Recent genetic studies have demonstrated that recurrent copy number variants (CNVs) are associated with a high risk for ASD [4]. The 3q29 microdeletion (3q29del) is typically an approximately 1.6 Mb deletion and contains 21 protein-coding genes [5]. Although the incidence of 3q29del is low (1 in 30,000–40,000 birth), 3q29del confers high risk for ASD both in males (odds ratio, 24.6) and females (odds ratio, 41.8), as well as for schizophrenia [6]. These exceptionally high odds ratios suggest that the cellular and molecular etiology of patients with 3q29del is an invaluable clue for elucidating the complex mechanisms of ASD. Recently, mouse models carrying a heterozygous deletion of the chromosomal region corresponding to the human 3q29 region (deficiency (Df)/+ mice) were generated and showed various neurodevelopmental and psychiatric conditions-related behavioral abnormalities, including ASD-related behavioral abnormalities [7, 8]. This highlights the relevance of Df/+ mice as an ASD model as well as various neurodevelopmental and psychiatric conditions with significant construct and face validity. Currently, the molecular pathogenesis of ASD-related phenotypes in Df/+ mice remains unclear. Recent studies have suggested that genetic variants of the oxytocin (OXT) receptor are associated with social behavior in humans and that impaired OXT signaling is linked to ASD [9]. In mice, targeted disruption of the Oxt or OXT receptor (Oxtr) gene impairs social behavior, suggesting that the OXT system plays an important role in social behavior across species [9]. Thus, focusing on the OXT system may provide clues to shed light on the molecular mechanisms regulating social behavior in mice. Currently, limited studies have shown a link between the OXT system and behavioral phenotypes in mouse models of ASD [for example see 10, 11]. In this study, to elucidate the molecular mechanisms behind impaired social behavior in Df/+ mice, we investigated the possible involvement of OXT signaling in impaired social behavior in Df/+ mice.

Results

To investigate whether oxytocin administration ameliorates impaired social behavior in Df/+ mice, we carried out a reciprocal social interaction test with the administration of 200 µg/kg of OXT (Fig. 1a). As we and other groups previously reported [7, 8], Df/+ mice treated with saline showed decreased social interaction time compared to that of WT littermates (Fig. 1b). We revealed that intraperitoneal administration of OXT improved impaired social interaction in Df/+ mice to a level similar to that in WT littermates (Fig. 1b). However, it did not have significant effect on the social interaction time in WT littermates at the concentration used (Fig. 1b).
Fig. 1

Administration of OXT improved impaired social interaction in Df/+ mice. a Timeline for the reciprocal social interaction test with OXT treatment. The test was carried out 30 min after administration of OXT (200 µg/kg) or saline. OXT, Oxytocin. b Social interaction time in the reciprocal social interaction test (each n = 12). The time spent sniffing, following, allo-grooming, and push-crawling of test mice toward the intruder was measured as social interaction time (two-way ANOVA for genotype, F1,44 = 8.84, P = 0.0048; for treatment, F1,44 = 4.61, P = 0.037; genotype × treatment interaction, F1,44 = 3.23, P = 0.079). WT, wild-type. c (upper) Schematic illustration of the PVN (green) and (lower) representative images of OXT-Neurophysin1 immunostaining (green) and hoechst33258 staining (blue) in the PVN of adult Df/+ mice and WT littermates. Scale bar, 100 μm. d Quantification of the number of OXT-positive cells in the PVN (each n = 4 mice). e ELISA quantification of the OXT concentration in the cerebral cortex extract (each n = 8 mice). f Quantitative real-time RT-PCR analysis of the expression levels of Oxtr and Avpr1a mRNA (each n = 4 mice). Oxtr, OXT receptor; Avpr1a, vasopressin receptor 1 A. Data are represented as the mean ± SEM. Statistical significance was analyzed by a two-way ANOVA, followed by Bonferroni Dunn post hoc tests (b) and Student’s t-test (d–f). *P < 0.05, ****P < 0.0001, n,s, not significant

Administration of OXT improved impaired social interaction in Df/+ mice. a Timeline for the reciprocal social interaction test with OXT treatment. The test was carried out 30 min after administration of OXT (200 µg/kg) or saline. OXT, Oxytocin. b Social interaction time in the reciprocal social interaction test (each n = 12). The time spent sniffing, following, allo-grooming, and push-crawling of test mice toward the intruder was measured as social interaction time (two-way ANOVA for genotype, F1,44 = 8.84, P = 0.0048; for treatment, F1,44 = 4.61, P = 0.037; genotype × treatment interaction, F1,44 = 3.23, P = 0.079). WT, wild-type. c (upper) Schematic illustration of the PVN (green) and (lower) representative images of OXT-Neurophysin1 immunostaining (green) and hoechst33258 staining (blue) in the PVN of adult Df/+ mice and WT littermates. Scale bar, 100 μm. d Quantification of the number of OXT-positive cells in the PVN (each n = 4 mice). e ELISA quantification of the OXT concentration in the cerebral cortex extract (each n = 8 mice). f Quantitative real-time RT-PCR analysis of the expression levels of Oxtr and Avpr1a mRNA (each n = 4 mice). Oxtr, OXT receptor; Avpr1a, vasopressin receptor 1 A. Data are represented as the mean ± SEM. Statistical significance was analyzed by a two-way ANOVA, followed by Bonferroni Dunn post hoc tests (b) and Student’s t-test (d–f). *P < 0.05, ****P < 0.0001, n,s, not significant To elucidate the molecular mechanism underlying the effect of OXT in Df/+ mice, we examined the abnormalities of OXT-related signaling pathways in Df/+ mice. We assessed the number of OXT neurons in the paraventricular nucleus (PVN), where OXT neurons are densely located [9], and found that the number of OXT-positive cells was significantly lower in Df/+ mice than in WT littermates (Fig. 1c and d). We assumed that the decreased number of OXT-positive cells in Df/+ mice may result in decreased OXT concentration in the cerebral cortex, where OXT signaling plays an important role in the regulation of social behavior. To probe this possibility, we quantified levels of OXT peptide in the cerebral cortex and found decreased levels of OXT peptide in the cerebral cortex of Df/+ mice as compared to that in WT littermates (Fig. 1e). Finally, we measured the expression of the Oxtr and vasopressin receptor 1 A (Avpr1a) mRNAs, which encodes for another receptor for OXT, in the cerebral cortex by quantitative real-time RT-PCR. Results showed that the expression levels of Oxtr and Avpr1a mRNAs were not significantly changed in Df/+ mice as compared to those in WT littermates (Fig. 1f).

Discussion

Df/+ mice show social dysfunction, one of the major ASD-related behavioral phenotypes. However, the molecular pathophysiological mechanisms underlying these phenotypes remain largely unclear. In this study, we provide evidence suggesting that impaired OXT system is associated with social dysfunction in Df/+ mice. Specifically, our current results offer a new avenue for investigating the molecular mechanisms underlying the effect of 3q29del on social symptoms. Considering that the 3q29del confers an extremely high risk for ASD as well as various neurodevelopmental and psychiatric conditions [6], our study may provide important insights into the molecular pathophysiological basis of ASD as well as various neurodevelopmental and psychiatric conditions. The molecular links between the OXT system and the 21 protein-coding genes in the 3q29 deleted region remain unknown. Among the 21 gene products, PAK2, which regulates actin cytoskeletal dynamics and dendritic spine morphology, is suggested to be mainly associated with ASD [10]. However, PAK2 mRNA expression is decreased by OXT treatment in the hippocampus [11], suggesting that PAK2 might not be involved in the effect of OXT in Df/+ mice. In addition to PAK2, a recent study suggests that four genes, including CEP19, SENP5, UBXN7, and WDR53, out of the 21 protein-coding genes in the 3q29-deleted region may be primary ASD-associated genes [12]. Unraveling the precise molecular links between impaired OXT system and dysfunction of these possible ASD-associated gene products will help elucidate the molecular pathophysiological mechanisms of social dysfunction in Df/+ mice. Several ASD mouse models, such as POGZ-Q1038R, Nlgn3−/−, and Cntnap2−/− mice, have an impaired OXT system [13-15]. This suggests that, despite the etiological heterogeneity of ASD, an impaired OXT system may underpin the social symptoms in a subset of patients. Considering that the social symptoms in the patients with 3q29del may be distinct from those in idiopathic ASD patients [6] and that the social symptoms are common features of various neurodevelopmental and psychiatric conditions, further studies on the possible molecular links between an impaired OXT system and social symptoms may help advance a molecular mechanism-based stratification of groups of patient with various neurodevelopmental and psychiatric conditions as well as the development of molecular pathogenesis-based therapeutic interventions, extending well beyond OXT treatment. Additional file 1. Detailed materials and methods.
  15 in total

1.  Abnormal neuronal morphology and altered synaptic proteins are restored by oxytocin in autism-related SHANK3 deficient model.

Authors:  Alexandra Reichova; Zuzana Bacova; Stanislava Bukatova; Martina Kokavcova; Veronika Meliskova; Karel Frimmel; Daniela Ostatnikova; Jan Bakos
Journal:  Mol Cell Endocrinol       Date:  2020-06-30       Impact factor: 4.102

2.  PAK2 Haploinsufficiency Results in Synaptic Cytoskeleton Impairment and Autism-Related Behavior.

Authors:  Yan Wang; Cheng Zeng; Jinchen Li; Zikai Zhou; Xingda Ju; Shuting Xia; Yuanyuan Li; An Liu; Huajing Teng; Kun Zhang; Leisheng Shi; Cheng Bi; Wei Xie; Xin He; Zhengping Jia; Yonghui Jiang; Tao Cai; Jinyu Wu; Kun Xia; Zhong Sheng Sun
Journal:  Cell Rep       Date:  2018-08-21       Impact factor: 9.423

3.  Prevalence of Autism Spectrum Disorder Among US Children and Adolescents, 2014-2016.

Authors:  Guifeng Xu; Lane Strathearn; Buyun Liu; Wei Bao
Journal:  JAMA       Date:  2018-01-02       Impact factor: 56.272

4.  Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism.

Authors:  F Kyle Satterstrom; Jack A Kosmicki; Jiebiao Wang; Michael S Breen; Silvia De Rubeis; Joon-Yong An; Minshi Peng; Ryan Collins; Jakob Grove; Lambertus Klei; Christine Stevens; Jennifer Reichert; Maureen S Mulhern; Mykyta Artomov; Sherif Gerges; Brooke Sheppard; Xinyi Xu; Aparna Bhaduri; Utku Norman; Harrison Brand; Grace Schwartz; Rachel Nguyen; Elizabeth E Guerrero; Caroline Dias; Catalina Betancur; Edwin H Cook; Louise Gallagher; Michael Gill; James S Sutcliffe; Audrey Thurm; Michael E Zwick; Anders D Børglum; Matthew W State; A Ercument Cicek; Michael E Talkowski; David J Cutler; Bernie Devlin; Stephan J Sanders; Kathryn Roeder; Mark J Daly; Joseph D Buxbaum
Journal:  Cell       Date:  2020-01-23       Impact factor: 41.582

5.  Comparative Analyses of Copy-Number Variation in Autism Spectrum Disorder and Schizophrenia Reveal Etiological Overlap and Biological Insights.

Authors:  Itaru Kushima; Branko Aleksic; Masahiro Nakatochi; Teppei Shimamura; Takashi Okada; Yota Uno; Mako Morikawa; Kanako Ishizuka; Tomoko Shiino; Hiroki Kimura; Yuko Arioka; Akira Yoshimi; Yuto Takasaki; Yanjie Yu; Yukako Nakamura; Maeri Yamamoto; Tetsuya Iidaka; Shuji Iritani; Toshiya Inada; Nanayo Ogawa; Emiko Shishido; Youta Torii; Naoko Kawano; Yutaka Omura; Toru Yoshikawa; Tokio Uchiyama; Toshimichi Yamamoto; Masashi Ikeda; Ryota Hashimoto; Hidenaga Yamamori; Yuka Yasuda; Toshiyuki Someya; Yuichiro Watanabe; Jun Egawa; Ayako Nunokawa; Masanari Itokawa; Makoto Arai; Mitsuhiro Miyashita; Akiko Kobori; Michio Suzuki; Tsutomu Takahashi; Masahide Usami; Masaki Kodaira; Kyota Watanabe; Tsukasa Sasaki; Hitoshi Kuwabara; Mamoru Tochigi; Fumichika Nishimura; Hidenori Yamasue; Yosuke Eriguchi; Seico Benner; Masaki Kojima; Walid Yassin; Toshio Munesue; Shigeru Yokoyama; Ryo Kimura; Yasuko Funabiki; Hirotaka Kosaka; Makoto Ishitobi; Tetsuro Ohmori; Shusuke Numata; Takeo Yoshikawa; Tomoko Toyota; Kazuhiro Yamakawa; Toshimitsu Suzuki; Yushi Inoue; Kentaro Nakaoka; Yu-Ichi Goto; Masumi Inagaki; Naoki Hashimoto; Ichiro Kusumi; Shuraku Son; Toshiya Murai; Tempei Ikegame; Naohiro Okada; Kiyoto Kasai; Shohko Kunimoto; Daisuke Mori; Nakao Iwata; Norio Ozaki
Journal:  Cell Rep       Date:  2018-09-11       Impact factor: 9.423

6.  Behavioral changes and growth deficits in a CRISPR engineered mouse model of the schizophrenia-associated 3q29 deletion.

Authors:  David Weinshenker; Tamara Caspary; Jennifer Gladys Mulle; Timothy P Rutkowski; Ryan H Purcell; Rebecca M Pollak; Stephanie M Grewenow; Georgette M Gafford; Tamika Malone; Uswa A Khan; Jason P Schroeder; Michael P Epstein; Gary J Bassell; Stephen T Warren
Journal:  Mol Psychiatry       Date:  2019-04-11       Impact factor: 15.992

7.  Convergent and distributed effects of the 3q29 deletion on the human neural transcriptome.

Authors:  Esra Sefik; Ryan H Purcell; Elaine F Walker; Gary J Bassell; Jennifer G Mulle
Journal:  Transl Psychiatry       Date:  2021-06-15       Impact factor: 6.222

8.  Psychiatric-disorder-related behavioral phenotypes and cortical hyperactivity in a mouse model of 3q29 deletion syndrome.

Authors:  Masayuki Baba; Kazumasa Yokoyama; Kaoru Seiriki; Yuichiro Naka; Kensuke Matsumura; Momoka Kondo; Kana Yamamoto; Misuzu Hayashida; Atsushi Kasai; Yukio Ago; Kazuki Nagayasu; Atsuko Hayata-Takano; Akinori Takahashi; Shun Yamaguchi; Daisuke Mori; Norio Ozaki; Tadashi Yamamoto; Kazuhiro Takuma; Ryota Hashimoto; Hitoshi Hashimoto; Takanobu Nakazawa
Journal:  Neuropsychopharmacology       Date:  2019-06-19       Impact factor: 7.853

Review 9.  Is Oxytocin "Nature's Medicine"?

Authors:  C Sue Carter; William M Kenkel; Evan L MacLean; Steven R Wilson; Allison M Perkeybile; Jason R Yee; Craig F Ferris; Hossein P Nazarloo; Stephen W Porges; John M Davis; Jessica J Connelly; Marcy A Kingsbury
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

Review 10.  Autism spectrum disorder.

Authors:  Catherine Lord; Traolach S Brugha; Tony Charman; James Cusack; Guillaume Dumas; Thomas Frazier; Emily J H Jones; Rebecca M Jones; Andrew Pickles; Matthew W State; Julie Lounds Taylor; Jeremy Veenstra-VanderWeele
Journal:  Nat Rev Dis Primers       Date:  2020-01-16       Impact factor: 52.329

View more
  1 in total

1.  Correction to: Oxytocin ameliorates impaired social behavior in a mouse model of 3q29 deletion syndrome.

Authors:  Tomoya Takemoto; Masayuki Baba; Kazumasa Yokoyama; Kohei Kitagawa; Kazuki Nagayasu; Yukio Ago; Kaoru Seiriki; Atsuko Hayata-Takano; Atsushi Kasai; Daisuke Mori; Norio Ozaki; Kazuhiro Takuma; Ryota Hashimoto; Hitoshi Hashimoto; Takanobu Nakazawa
Journal:  Mol Brain       Date:  2022-04-11       Impact factor: 4.041

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.